Loading
No insider purchase over the last 90 days. The latest, by 高序英, was filed 26 Jun 2026.
Chongqing Jiheng Pharmaceutical Co., Ltd.: what insiders have been doing
Every trade that managers of Chongqing Jiheng Pharmaceutical Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Chemicals sector. From 26 October 2025 to 26 October 2026, the disclosure feed for Chongqing Jiheng Pharmaceutical Co., Ltd. logged 1 filing by 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €22k, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 高序英 filed the largest purchase, €22k, on 26 June 2026. Among those who bought: 1 chief executive.
With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 533 companies we follow on the same exchange. The full history, which starts in 2021, counts 1 purchase against 4 sales.
The last insider purchase was made public on 26 June 2026, 122 days ago.
In the same sector, recent insider purchases at Culp Inc also feature in our signals. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Insider Decl.
5
Thresholds
n/a
Buy Volume
€22,176
1 ops. · all time
Sell Volume
€2M
4 ops. · all time
Who traded when
BuySale高序英1 buy
Since the insiders bought
- +21.3%Entry CN¥3.38 · Close at T+90 CN¥4.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,683 of 26,320 companies
17.1
score / 100
Value22
Quality12
FCF yld-1.4%
Earn yld-16%
EV/EBITDA·
ROE·
Gross mgn16%
Net mgn-47%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥3.95
Analyst consensus
Income statement
RevenueCN¥899.8M
Gross profitCN¥141.1M16% margin
EBITDA-CN¥142.3M-16% margin
Net income-CN¥419.7M-47.2% margin
Valuation
P/Book18.2x
Beta0.50
Balance sheet & cash
Market capCN¥2.7B
Total debtCN¥526.1M
Free Cash Flow-CN¥35.3M
Debt / Equity221%
Profitability & ownership
ROA-3.6%
% insiders45.6%
% institutions0.0%
Last declaration on 26 June 2026
Declarations5 total
52,000 shares@ CN¥25.3813100.0% of flowA股XSHESZSE:273000000765533730
Canonical exit: 24 Sept 2026 (T+90)
121,500 shares4.1% of flowA股XSHESZSE:173000004508674300
38,400 shares1.3% of flowA股XSHESZSE:173000004503946750
582,235 shares21.7% of flowA股XSHESZSE:173000004467157060
1,905,454 shares72.9% of flowA股XSHESZSE:173000004474808260
5 of 5 declarations
About Chongqing Jiheng Pharmaceutical Co., Ltd.
三圣股份 is a company specializing in the chemical and materials sector. It is listed on the XSHE market.
